New agent might control breast-cancer growth and spread

April 22, 2013
The drug AS1411 works by blocking the cell's production of regulatory molecules called microRNA, some types of which are associated with cancer. Specifically, the drug inhibits a protein called nucleolin that plays a critical role in the microRNA maturation process. Left: Steps in the microRNA maturation process. Right: How AS1411 interferes with microRNA maturation. Credit: The Ohio State University Comprehensive Cancer Center

A new study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) suggests that an unusual experimental drug can reduce breast-cancer aggressiveness, reverse resistance to the drug fulvestrant and perhaps improve the effectiveness of other breast-cancer drugs.

The findings of the laboratory and animal study, published in the Journal of Experimental Medicine, suggest a new strategy for treating breast cancer, the researchers say.

The drug, called AS1411, belongs to a class of agents called G-rich aptamers. The agent works by blocking the cell's production of molecules called microRNA, some types of which are associated with cancer. Specifically, the drug inhibits a protein called nucleolin that plays a critical role in the microRNA (See figure).

MicroRNA molecules help cells control the amount and kinds of proteins they make, and abnormal levels of certain microRNAs are a hallmark of many cancers.

"This study of the role of nucleolin in micro RNA regulation has clear clinical implications," says principal investigator Dr. Carlo M. Croce, director of Ohio State's program and a member of the OSUCCC – James Molecular Biology and Cancer Genetics program.

"It supports a novel treatment for breast cancer that reduces cancer aggressiveness and restores drug-sensitivity by inhibiting the processing of specific microRNAs that are highly expressed in cancers."

First author Flavia Pichiorri, assistant professor of hematology, notes that nucleolin is a promising for microRNA modulation in .

"To our knowledge, this is the first large study to show a clear association between nucleolin and specific microRNAs that are causally involved in cancer," she says. "We also believe it is the first study to show that targeting nucleolin with a G-rich can control breast-cancer metastasis in an animal model through microRNA regulation."

The study's key technical findings include:

  • Nucleolin is present at abnormally high levels in breast cancer cells.
  • AS1411 reduces nucleolin levels and inhibits the processing of certain cancer-associated microRNAs, including miR-21, miR-103, miR-221 and miR-222, whose overexpression in breast cancer is associated with drug resistance and aggressiveness.
  • AS1411 affects breast-cancer-cell motility and invasiveness by reducing the expression of several genes targeted by nucleolin-related microRNAs (e.g., PTEN);
  • Impairing nucleolin in fulvestrant-resistant cells restores sensitivity to the drug, suggesting that agents targeting nucleolin can improve the effectiveness of conventional anti-cancer agents.

Explore further: How early breast tumors become deadly: A small group of molecules might hold the answer

Related Stories

How early breast tumors become deadly: A small group of molecules might hold the answer

February 7, 2012
Researchers have discovered a restricted pattern of molecules that differentiate early-stage breast tumors from invasive, life-threatening cancer. They also found a similar molecular signature that correlated with the aggressiveness ...

Study reveals mechanism of lung-cancer drug resistance

January 19, 2012
New research published in Nature Medicine indicates that targeted drugs such as gefitinib might more effectively treat non-small cell lung cancer if they could be combined with agents that block certain microRNAs.

MicroRNA controls malignancy and resistance of breast cancer cells

May 4, 2012
Many breast cancer patients are treated with a drug called tamoxifen. The substance blocks the effect of estrogen and thus suppresses the growth signals of this hormone in cancer cells. When resistance to the drug develops, ...

MicroRNA molecule may serve as biomarker, target for brain metastases in breast cancer patients

February 5, 2013
Researchers have identified two molecules that could potentially serve as biomarkers in predicting brain metastases in patients with breast cancer, according to data published in Cancer Research, a publication of the American ...

miR loss may power maligant transformation in chronic leukemia

July 5, 2012
Loss of a particular microRNA in chronic lymphocytic leukemia shuts down normal cell metabolism and turns up alternative mechanisms that enable cancer cells to produce the energy and build the molecules they need to proliferate ...

Recommended for you

Study prompts new ideas on cancers' origins

December 16, 2017
Rapidly dividing, yet aberrant stem cells are a major source of cancer. But a new study suggests that mature cells also play a key role in initiating cancer—a finding that could upend the way scientists think about the ...

What does hair loss have to teach us about cancer metastasis?

December 15, 2017
Understanding how cancer cells are able to metastasize—migrate from the primary tumor to distant sites in the body—and developing therapies to inhibit this process are the focus of many laboratories around the country. ...

Cancer immunotherapy may work better in patients with specific genes

December 15, 2017
Cancer cells arise when DNA is mutated, and these cells should be recognized as "foreign" by the immune system. However, cancer cells have found ways to evade detection by the immune system.

Scientists pinpoint gene to blame for poorer survival rate in early-onset breast cancer patients

December 15, 2017
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.